Lista de obras - Emma Hall - Dominio Público Uruguay

2043 Defining bowel dose constraints for bladder radiotherapy: using data from patients entered into phase III randomised trial

2507 Prognostic factors in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004)

497 oral PHASE III PILOT STUDY OF DOSE ESCALATION USING CON-FORMAL RADIOTHERAPY IN PROSTATE CANCER: LONG TERM FOLLOW UP

7102 Updated results of the BC2001 phase III randomized trial of standard vs reduced high dose volume radiotherapy for muscle invasive bladder cancer (ISCRTN:68324339): tumour control, toxicity and quality of life

article

A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity

artículo científico publicado en 2014

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

artículo científico publicado en 2004

A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1.

artículo científico publicado en 2014

Alcohol and coronary heart disease reduction among British doctors: confounding or causality?

artículo científico publicado en 1997

Benefits and challenges of electronic data capture (EDC) systems versus paper case report forms.

artículo científico publicado en 2015

Boxing Bladder Cancer with COX-2-specific Inhibition

artículo científico publicado en 2011

CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer

scientific article published on 03 March 2020

Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.

artículo científico publicado en 2017

Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy

artículo científico publicado en 2017

Clinical development of new drug-radiotherapy combinations ⬇️

artículo científico publicado en 2016

Clinical trial design for non-muscle-invasive bladder cancer

artículo científico publicado en 2023

Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative ⬇️

artículo científico publicado en 2014

Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity

artículo científico publicado en 2016

Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/00

artículo científico publicado en 2014

Consensus Guidelines and Contouring Atlas for Pelvic Node Delineation in Prostate and Pelvic Node Intensity Modulated Radiation Therapy.

artículo científico publicado en 2015

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

artículo científico publicado en 2016

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial

article

Current attitudes of head and neck oncologists in the United Kingdom to induction chemotherapy for locally advanced head and neck cancer: A survey of centres participating in a national randomised controlled trial

artículo científico publicado en 2013

DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer

artículo científico publicado en 2016

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer ⬇️

artículo científico publicado en 2015

Defining bowel dose volume constraints for bladder radiotherapy treatment planning

artículo científico publicado en 2014

Design considerations when transitioning from paper case report forms (CRFS) to electronic data capture (EDC).

artículo científico publicado en 2015

Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study.

artículo científico publicado en 2016

Diffusion-weighted MRI in Advanced Epithelial Ovarian Cancer: Apparent Diffusion Coefficient as a Response Marker

artículo científico publicado en 2019

Dosimetric explanations of fatigue in head and neck radiotherapy: an analysis from the PARSPORT Phase III trial.

artículo científico publicado en 2012

Double-blind placebo-controlled randomised trial of vitamin E and pentoxifylline in patients with chronic arm lymphoedema and fibrosis after surgery and radiotherapy for breast cancer.

artículo científico publicado en 2004

Double-blind, placebo-controlled, randomised phase II trial of IH636 grape seed proanthocyanidin extract (GSPE) in patients with radiation-induced breast induration

article

Dynamic prediction methods in the BC2001 clinical trial.

artículo científico publicado en 2015

First Toxicity Report of the BC2001 Trial: A Multicentre Phase III Randomised Trial of Radiotherapy with and without Synchronous Chemotherapy in Muscle Invasive Bladder Cancer ISCRTN No. 68324339, EUDRACT No. 2004-000164-26

article

HYBRID — Evaluating New Radiation Technology in Patients with Unmet Needs

article

Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy

artículo científico publicado en 2007

Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

artículo científico publicado en 2015

Hypofractionation for Prostate Cancer: Time to Change

artículo científico publicado en 2016

Impact of selenium on mood and quality of life: a randomized, controlled trial

artículo científico publicado en 2005

Implementing electronic data capture (EDC) training for site staff.

artículo científico publicado en 2015

Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study

artículo científico publicado en 2011

Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients

artículo científico publicado en 2016

Intermittent androgen suppression for rising PSA level after radiotherapy

artículo científico publicado en 2012

Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study

artículo científico publicado en 2020

Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey

artículo científico publicado en 2016

Introducing the Cancer Research UK Advanced Radiotherapy Technologies Network (ART-NET). ⬇️

artículo científico publicado en 2017

Is High Dose Therapy Superior to Conventional Dose Therapy as Initial Treatment for Relapsed Germ Cell Tumors? The TIGER Trial ⬇️

artículo científico publicado el 1 de enero de 2011

LIFE AND DEATH OF SPARE (SELECTIVE BLADDER PRESERVATION AGAINST RADICAL EXCISION): REFLECTIONS ON WHY THE SPARE TRIAL CLOSED

article

Letter in response to the Wedlake et al. paper 'Evaluating the efficacy of statins and ACE-inhibitors in reducing gastrointestinal toxicity in patients receiving radiotherapy for pelvic malignancies'.

artículo científico publicado en 2013

Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)--a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen.

artículo científico publicado en 2009

Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer

artículo científico publicado en 2016

Mortality in relation to consumption of alcohol: 13 years' observations on male British doctors.

artículo científico publicado en 1994

Non-randomised phase II trial of hyperbaric oxygen therapy in patients with chronic arm lymphoedema and tissue fibrosis after radiotherapy for early breast cancer

artículo científico publicado en 2004

Novel approaches to improve the therapeutic index of head and neck radiotherapy: an analysis of data from the PARSPORT randomised phase III trial

artículo científico publicado en 2012

Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial

artículo científico publicado en 2011

Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial

scientific article published on 13 December 2019

Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: results at 4 years.

artículo científico publicado en 2005

Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers

artículo científico publicado en 2020

Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to biomarker defined subgroups.

artículo científico publicado en 2011

Phase II study of vitamin E and pentoxifylline in patients with late side effects of pelvic radiotherapy

artículo científico publicado en 2005

Phase III trial of conformal radiotherapy following neoadjuvant hormone treatment in early prostate cancer

Prostate cancer and hypofractionation: reflections on recent randomised phase III clinical trial results

artículo científico publicado en 2017

Quality assuring "Plan of the day" selection in a multicentre adaptive bladder trial: Implementation of a pre-accrual IGRT guidance and assessment module

artículo científico publicado en 2019

Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer

artículo científico publicado en 2006

R-IDEAL: A Framework for Systematic Clinical Evaluation of Technical Innovations in Radiation Oncology

scientific article published on 03 April 2017

Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer

article

Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up

artículo científico publicado en 2013

Randomized controlled trial of the effect of selenium supplementation on thyroid function in the elderly in the United Kingdom

artículo científico publicado en 2008

Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004)

artículo científico publicado en 2013

Re: Marco Roscigno, Maurizio Brausi, Axel Heidenreich, et al. Lymphadenectomy at the Time of Nephroureterectomy for Upper Tract Urothelial Cancer. Eur Urol 2011;60:776–83

artículo científico publicado en 2011

Recovery of Salivary Function: Contralateral Parotid-sparing Intensity-modulated Radiotherapy versus Bilateral Superficial Lobe Parotid-sparing Intensity-modulated Radiotherapy

artículo científico publicado en 2016

Remote training solutions for complex intervention trials.

artículo científico publicado en 2015

Results of a 2 x 2 Phase III Randomized Trial of Synchronous Chemo-radiotherapy (CRT) Compared to Radiotherapy (RT) Alone and Standard vs. Reduced High Volume RT in Muscle Invasive Bladder Cancer (MIBC) (BC2001 CRUK/01/004)

Results of a Phase III Multi-centre Randomised Controlled Trial of Intensity Modulated (IMRT) vs Conventional Radiotherapy (RT) in Head and Neck Cancer (PARSPORT: ISRCTN48243537; CRUK/03/005)

article by C. Nutting et al published December 2010 in Clinical Oncology

Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma

artículo científico publicado en 2013

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial

artículo científico publicado en 2009

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study

artículo científico publicado en 2007

The Patient Deficit Model Overturned: a qualitative study of patients' perceptions of invitation to participate in a randomized controlled trial comparing selective bladder preservation against surgery in muscle invasive bladder cancer (SPARE, CRUK/

artículo científico publicado en 2012

The Radiotherapy Clinical Trial Research Landscape in the UK Between 2004 and 2013: A Cross-sectional Analysis

artículo científico publicado en 2015

The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004).

artículo científico publicado en 2017

Time to define an international standard of postoperative care for resected upper urinary tract transitional cell carcinoma (TCC) - opening of the peri-operative chemotherapy versus surveillance in upper tract urothelial cancer (POUT) Trial

artículo científico publicado en 2012

Triplet therapy with palbociclib, taselisib and fulvestrant in PIK3CA mutant breast cancer and doublet palbociclib and taselisib in pathway mutant solid cancers

scientific article published on 21 September 2020

Two-Year and Lifetime Cost-Effectiveness of Intensity Modulated Radiation Therapy Versus 3D Conformal Radiation Therapy for Head-and-Neck Cancer

article by N.C. Sheets et al published October 2013 in International Journal of Radiation Oncology Biology Physics

Two-year and lifetime cost-effectiveness of intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy for head-and-neck cancer

artículo científico publicado en 2013

Using a Bayesian approach with reverse philosophy to design clinical trials in rare diseases

artículo científico publicado en 2013

Validation and reliability testing of the EORTC QLQ-NMIBC24 questionnaire module to assess patient-reported outcomes in non-muscle-invasive bladder cancer.

artículo científico publicado en 2014

Lista de obras de Emma Hall

2043 Defining bowel dose constraints for bladder radiotherapy: using data from patients entered into phase III randomised trial

2507 Prognostic factors in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004)

497 oral PHASE III PILOT STUDY OF DOSE ESCALATION USING CON-FORMAL RADIOTHERAPY IN PROSTATE CANCER: LONG TERM FOLLOW UP

7102 Updated results of the BC2001 phase III randomized trial of standard vs reduced high dose volume radiotherapy for muscle invasive bladder cancer (ISCRTN:68324339): tumour control, toxicity and quality of life

A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1.

Alcohol and coronary heart disease reduction among British doctors: confounding or causality?

Benefits and challenges of electronic data capture (EDC) systems versus paper case report forms.

Boxing Bladder Cancer with COX-2-specific Inhibition

CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer

Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.

Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy

Clinical development of new drug-radiotherapy combinations ⬇️

Clinical trial design for non-muscle-invasive bladder cancer

Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative ⬇️

Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity

Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/00

Consensus Guidelines and Contouring Atlas for Pelvic Node Delineation in Prostate and Pelvic Node Intensity Modulated Radiation Therapy.

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial

Current attitudes of head and neck oncologists in the United Kingdom to induction chemotherapy for locally advanced head and neck cancer: A survey of centres participating in a national randomised controlled trial

DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer ⬇️

Defining bowel dose volume constraints for bladder radiotherapy treatment planning

Design considerations when transitioning from paper case report forms (CRFS) to electronic data capture (EDC).

Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study.

Diffusion-weighted MRI in Advanced Epithelial Ovarian Cancer: Apparent Diffusion Coefficient as a Response Marker

Dosimetric explanations of fatigue in head and neck radiotherapy: an analysis from the PARSPORT Phase III trial.

Double-blind placebo-controlled randomised trial of vitamin E and pentoxifylline in patients with chronic arm lymphoedema and fibrosis after surgery and radiotherapy for breast cancer.

Double-blind, placebo-controlled, randomised phase II trial of IH636 grape seed proanthocyanidin extract (GSPE) in patients with radiation-induced breast induration

Dynamic prediction methods in the BC2001 clinical trial.

First Toxicity Report of the BC2001 Trial: A Multicentre Phase III Randomised Trial of Radiotherapy with and without Synchronous Chemotherapy in Muscle Invasive Bladder Cancer ISCRTN No. 68324339, EUDRACT No. 2004-000164-26

HYBRID — Evaluating New Radiation Technology in Patients with Unmet Needs

Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy

Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

Hypofractionation for Prostate Cancer: Time to Change

Impact of selenium on mood and quality of life: a randomized, controlled trial

Implementing electronic data capture (EDC) training for site staff.

Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study

Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients

Intermittent androgen suppression for rising PSA level after radiotherapy

Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study

Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey

Introducing the Cancer Research UK Advanced Radiotherapy Technologies Network (ART-NET). ⬇️

Is High Dose Therapy Superior to Conventional Dose Therapy as Initial Treatment for Relapsed Germ Cell Tumors? The TIGER Trial ⬇️

LIFE AND DEATH OF SPARE (SELECTIVE BLADDER PRESERVATION AGAINST RADICAL EXCISION): REFLECTIONS ON WHY THE SPARE TRIAL CLOSED

Letter in response to the Wedlake et al. paper 'Evaluating the efficacy of statins and ACE-inhibitors in reducing gastrointestinal toxicity in patients receiving radiotherapy for pelvic malignancies'.

Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)--a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen.

Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer

Mortality in relation to consumption of alcohol: 13 years' observations on male British doctors.

Non-randomised phase II trial of hyperbaric oxygen therapy in patients with chronic arm lymphoedema and tissue fibrosis after radiotherapy for early breast cancer

Novel approaches to improve the therapeutic index of head and neck radiotherapy: an analysis of data from the PARSPORT randomised phase III trial

Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial

Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial

Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: results at 4 years.

Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers

Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to biomarker defined subgroups.

Phase II study of vitamin E and pentoxifylline in patients with late side effects of pelvic radiotherapy

Phase III trial of conformal radiotherapy following neoadjuvant hormone treatment in early prostate cancer

Prostate cancer and hypofractionation: reflections on recent randomised phase III clinical trial results

Quality assuring "Plan of the day" selection in a multicentre adaptive bladder trial: Implementation of a pre-accrual IGRT guidance and assessment module

Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer

R-IDEAL: A Framework for Systematic Clinical Evaluation of Technical Innovations in Radiation Oncology

Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer

Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up

Randomized controlled trial of the effect of selenium supplementation on thyroid function in the elderly in the United Kingdom

Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004)

Re: Marco Roscigno, Maurizio Brausi, Axel Heidenreich, et al. Lymphadenectomy at the Time of Nephroureterectomy for Upper Tract Urothelial Cancer. Eur Urol 2011;60:776–83

Recovery of Salivary Function: Contralateral Parotid-sparing Intensity-modulated Radiotherapy versus Bilateral Superficial Lobe Parotid-sparing Intensity-modulated Radiotherapy

Remote training solutions for complex intervention trials.

Results of a 2 x 2 Phase III Randomized Trial of Synchronous Chemo-radiotherapy (CRT) Compared to Radiotherapy (RT) Alone and Standard vs. Reduced High Volume RT in Muscle Invasive Bladder Cancer (MIBC) (BC2001 CRUK/01/004)

Results of a Phase III Multi-centre Randomised Controlled Trial of Intensity Modulated (IMRT) vs Conventional Radiotherapy (RT) in Head and Neck Cancer (PARSPORT: ISRCTN48243537; CRUK/03/005)

Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study

The Patient Deficit Model Overturned: a qualitative study of patients' perceptions of invitation to participate in a randomized controlled trial comparing selective bladder preservation against surgery in muscle invasive bladder cancer (SPARE, CRUK/

The Radiotherapy Clinical Trial Research Landscape in the UK Between 2004 and 2013: A Cross-sectional Analysis

The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004).